Product Description
For blocking the progression of pulmonary fibrosis and improving lung function in patients with COVID-19. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04334265)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Peking University First Hospital
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03568578 |
2017ZX10203202002 | N/A |
Unknown status |
Hepatitis B|Liver Cirrhosis|Hepatitis A |
2020-12-31 |
2021-10-02 |
||
NCT04334265 |
2020 research 110 | N/A |
Unknown status |
COVID-19 |
2020-06-01 |
2022-04-06 |
Primary Endpoints|Treatments|Trial Status |
|
ChiCTR-IOR-14005474 |
ChiCTR-IOR-14005474 | N/A |
Recruiting |
Liver Cirrhosis |
2015-12-31 |
Recent News Events
Date |
Type |
Title |
|---|